mGluR1 and mGluR5 antagonists in the amygdala inhibit different components of audible and ultrasonic vocalizations in a model of arthritic pain.
Pain has a strong emotional component. The amygdala plays a key role in emotionality and is also involved in pain processing and pain modulation. Our previous studies showed an important role of group I metabotropic glutamate receptors (mGluRs) in pain-related synaptic plasticity and sensitization of neurons in the central nucleus of the amygdala (CeA). Here we address the roles of mGluR1 and mGluR5 subtypes in the CeA in the modulation of supraspinally organized behavioral responses in a model of arthritic pain. Audible and ultrasonic (25+/-4 kHz) vocalizations were measured in awake rats during and after innocuous and noxious stimulation (15 s) of the knee joint. Vocalizations were recorded in the same animals before arthritis, 6 h after arthritis induction and during administration of antagonists selective for mGluR1 (CPCCOEt) and mGluR5 (MPEP) into the CeA through stereotaxically implanted microdialysis probes. The duration of audible and ultrasonic vocalizations increased in the arthritic pain state. The duration of vocalizations during stimulation (VDS), which are organized at the brainstem level, was significantly reduced by CPCCOEt but not by MPEP. Vocalizations that continued after stimulation (VAS), which are organized in the limbic forebrain, particularly the amygdala, were inhibited by CPCCOEt and MPEP. These findings suggest differential roles of mGluR1 and mGluR5 in the CeA in pain-related vocalizations. Both mGluR1 and mGluR5 contribute to vocalizations generated in the amygdala whereas mGluR1, but not mGluR5, is involved in the amygdala-mediated modulation of vocalizations originating from activity in the brainstem.
Han
Jeong Seok
JS
Department of Neuroscience and Cell Biology, The University of Texas Medical Branch, 301 University Blvd. RT 1069, Galveston, TX 77555-1069, USA.
Neugebauer
Volker
V
D000679:Amygdala / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D000704:Analysis of Variance; D000818:Animals; D001168:Arthritis / Q000139:chemically induced / Q000503:physiopathology*; D044723:Chondrus; D002867:Chromones / Q000494:pharmacology; D004195:Disease Models, Animal; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D008297:Male; D017551:Microdialysis / Q000379:methods; D010146:Pain / Q000139:chemically induced / Q000503:physiopathology*; D010812:Physical Stimulation; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors / Q000502:physiology*; D014828:Vocalization, Animal / Q000187:drug effects* / Q000502:physiology
C117789:7-(hydroxyimino)cyclopropan(b)chromen-1a-carbxoylic acid ethyl ester; D002867:Chromones; D018691:Excitatory Amino Acid Antagonists; C578937:Grm5 protein, rat; D011725:Pyridines; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate; C104077:metabotropic glutamate receptor type 1; C121465:6-methyl-2-(phenylethynyl)pyridine